Profile data is unavailable for this security.
About the company
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
- Revenue in USD (TTM)161.10m
- Net income in USD-308.60m
- Incorporated2014
- Employees445.00
- LocationArvinas Inc5 Science ParkNEW HAVEN 06511-1966United StatesUSA
- Phone+1 (203) 535-1456
- Fax+1 (302) 636-5454
- Websitehttps://www.arvinas.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.65bn | 174.00 | -- | 2.97 | -- | 16.21 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.65bn | 280.00 | -- | 2.28 | -- | 19.41 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.70bn | 526.00 | -- | 1.77 | -- | 39.44 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Dynavax Technologies Corp | 249.70m | 17.18m | 1.70bn | 408.00 | 128.67 | 2.65 | 78.69 | 6.83 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Bicycle Therapeutics PLC (ADR) | 36.90m | -166.28m | 1.72bn | 284.00 | -- | 2.07 | -- | 46.71 | -3.28 | -3.28 | 0.7163 | 12.04 | 0.0451 | -- | 0.9806 | 129,922.50 | -20.33 | -29.45 | -22.03 | -32.98 | -- | -- | -450.64 | -571.36 | -- | -- | 0.0002 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.86bn | 112.00 | -- | 5.09 | -- | 116.35 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.86bn | 445.00 | -- | 3.18 | -- | 11.58 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Viridian Therapeutics Inc | 288.00k | -228.06m | 1.92bn | 96.00 | -- | 4.89 | -- | 6,682.95 | -4.25 | -4.25 | 0.0053 | 8.29 | 0.0006 | -- | 5.65 | 3,063.83 | -48.67 | -55.59 | -52.32 | -60.32 | -- | -- | -79,185.77 | -5,678.12 | -- | -- | 0.0372 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Disc Medicine Inc | 0.00 | -91.00m | 1.93bn | 74.00 | -- | 3.95 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.94bn | 284.00 | -- | 4.87 | -- | 34.32 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Mirum Pharmaceuticals Inc | 264.38m | -109.16m | 2.00bn | 294.00 | -- | 8.73 | -- | 7.58 | -2.40 | -2.40 | 5.81 | 4.81 | 0.4788 | 5.06 | 5.52 | 1,001,424.00 | -19.77 | -38.93 | -23.38 | -44.88 | 72.27 | -- | -41.29 | -190.71 | 3.09 | -- | 0.573 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Spyre Therapeutics Inc | 0.00 | -185.98m | 2.01bn | 50.00 | -- | 9.20 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| MannKind Corp | 248.37m | 11.74m | 2.02bn | 414.00 | 204.77 | -- | 116.64 | 8.13 | 0.0359 | 0.0359 | 0.834 | -0.8226 | 0.656 | 2.85 | 9.71 | 599,937.20 | 3.10 | -26.07 | 4.05 | -37.80 | 71.29 | 59.68 | 4.73 | -57.61 | 3.76 | 1.86 | 1.89 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 2.04bn | 500.00 | -- | 3.87 | -- | 31.22 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Arvinas Inc's reporting currency: US Dollar USD
55.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Aug 2024 | 7.04m | 10.26% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 6.73m | 9.80% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.08m | 7.40% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 3.87m | 5.63% |
| Avidity Partners Management LPas of 30 Jun 2024 | 2.99m | 4.35% |
| RTW Investments LPas of 30 Jun 2024 | 2.97m | 4.32% |
| Citadel Advisors LLCas of 30 Jun 2024 | 2.53m | 3.69% |
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 2.44m | 3.55% |
| Bellevue Asset Management AGas of 30 Jun 2024 | 2.39m | 3.48% |
| Commodore Capital LPas of 30 Jun 2024 | 1.88m | 2.75% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
